Hsp90 inhibitor-mediated disruption of chaperone association of ATR with Hsp90 sensitizes cancer cells to DNA damage

Molecular Cancer Therapeutics

Volumn 10, Issue 7, 2011, Pages 1194-1206

  Ha, Kyungsoo ^a   Fiskus, Warren ^b   Rao, Rekha ^b   Balusu, Ramesh ^b   Venkannagari, Sreedhar ^b   Nalabothula, Narasimha Rao ^b   Bhalla, Kapil N ^b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF KANSAS CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; ATR PROTEIN; BORTEZOMIB; CHAPERONE; CHECKPOINT KINASE 1; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE H2AX; RESORCINYLIC ISOXAZOLE AMIDE; SHORT HAIRPIN RNA; TANESPIMYCIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CLONOGENESIS; DNA DAMAGE; GAMMA RADIATION; HUMAN; HUMAN CELL; IONIZING RADIATION; PRIORITY JOURNAL; PROTEIN DEPLETION; UBIQUITINATION; UTERINE CERVIX CANCER;

CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; DNA DAMAGE; DNA REPAIR; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HELA CELLS; HISTONES; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASMS; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN KINASES; PROTEIN TRANSPORT; PROTEIN-SERINE-THREONINE KINASES; RADIATION TOLERANCE; RADIATION, IONIZING; RADIATION-SENSITIZING AGENTS; RNA, SMALL INTERFERING;

EID: 79960134213     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0094     Document Type: Article

References (46)

1. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 2003;3:155-68. (Pubitemid 37328868)
2. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature 2004;432:316-23. (Pubitemid 39551659)
3. Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell 2010;40:179-204.
4. Cimprich KA, Cortez D. ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol 2008;9:616-27. (Pubitemid 352032926)
5. de Klein A, Muijtjens M, van Os R, Verhoeven Y, Smit B, Carr AM, et al. Targeted disruption of the cell-cycle checkpoint gene ATR leads to early embryonic lethality in mice. Curr Biol 2000;10:479-82. (Pubitemid 30247338)
6. Brown EJ, Baltimore D. ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev 2000;14: 397-402. (Pubitemid 30131885)
7. Cortez D, Guntuku S, Qin J, Elledge SJ. ATR and ATRIP: partners in checkpoint signaling. Science 2001;294:1713-16. (Pubitemid 33104841)
8. Zou L, Liu D, Elledge SJ. Replication protein A-mediated recruitment and activation of Rad17 complexes. Proc Natl Acad Sci U S A 2003;100:13827-32. (Pubitemid 37499151)
9. Kumagai A, Lee J, Yoo HY, Dunphy WG. TopBP1 activates the ATRATRIP complex. Cell 2006;124:943-55.
10. Helt CE, Cliby WA, Keng PC, Bambara RA, O'Reilly MA. Ataxia telangiectasia mutated (ATM) and ATM and Rad3-related protein exhibit selective target specificities in response to different forms of DNA damage. J Biol Chem 2005;280:1186-92.
11. Sørensen CS, Syljuåsen RG, Falck J, Schroeder T, Rönnstrand L, Khanna KK, et al. Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A. Cancer Cell 2003;3:247-58. (Pubitemid 37443880)
12. Mailand N, Falck J, Lukas C, Syljuâsen RG, Welcker M, Bartek J, et al. Rapid destruction of human Cdc25A in response to DNA damage. Science 2000;288:1425-29.
13. Zhao H, Watkins JL, Piwnica-Worms H. Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints. Proc Natl Acad Sci U S A 2002;99:14795-14800. (Pubitemid 35334563)
14. Zhou BB, Bartek J. Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer 2004;4:216-25. (Pubitemid 38337501)
15. Takai H, Wang RC, Takai KK, Yang H, de Lange T. Tel2 rgulates the stability of PI3K-related protein kinases. Cell 2007;131: 1248-59. (Pubitemid 350297416)
16. Takai H, Xie Y, de Lange T, Pavletich NP. Tel2 structure and function in the Hsp90-dependent maturation of mTOR and ATR complexes. Genes Dev 2010;24:2019-30.
17. Taipale M, Jarosz DF, Lindquist S. HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 2010;11:515-28.
18. Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 2010;10:537-49.
19. Arlander SJ, Eapen AK, Vroman BT, McDonald RJ, Toft DO, Karnitz LM. Hsp90 Inhibition Depletes Chk1 and Sensitizes Tumor Cells to Replication Stress. J Biol Chem 2003;278:52572-77. (Pubitemid 38035854)
20. Dote H, Burgan WE, Camphausen K, Tofilon PJ. Inhibition of hsp90 compromises the DNA damage response to radiation. Cancer Res 2006;66:9211-20. (Pubitemid 44521142)
21. Noguchi M, Yu D, Hirayama R, Ninomiya Y, Sekine E, Kubota N, et al. Inhibition of homologous recombination repair in irradiated tumor cells pretreated with Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Biochem Biophys Res Commun 2006;351:658-63. (Pubitemid 44708858)
22. Sekimoto T, Oda T, Pozo FM, Murakumo Y, Masutani C, Hanaoka F, et al. The molecular chaperone hsp90 regulates accumulation of DNA polymerase h at replication stalling sites in UV-irradiated cells. Mol Cell 2010;37:79-89.
23. Oda T, Hayano T, Miyaso H, Takahashi N, Yamashita T. Hsp90 regulates the Fanconi anemia DNA damage response pathway. Blood 2007;109:5016-26. (Pubitemid 46827802)
24. Jensen MR, Schoepfer J, Radimerski T, Massey A, Guy CT, Brueggen J, et al. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res 2008;10:R33.
25. Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, Valenti M, et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 2008;68:2850-60. (Pubitemid 351556284)
26. Gaspar N, Sharp SY, Eccles SA, Gowan S, Popov S, Jones C, et al. Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma. Mol Cancer Ther 2010;9:1219-33.
27. Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A, Markovina S, et al. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res 2003;63: 8984-95.
28. Stingl L, Stühmer T, Chatterjee M, Jensen MR, Flentje M, Djuzenova CS. Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction. Br J Cancer 2010;102: 1578-91.
29. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc 2006;1:2315-9.
30. Rao R, Nalluri S, Kolhe R, Yang Y, Fiskus W, Chen J, et al. Treatment with panobinostat induces glucose-regulated protein 78 acetylation and endoplasmic reticulum stress in breast cancer cells. Mol Cancer Ther 2010;9:942-52.
31. Mari PO, Florea BI, Persengiev SP, Verkaik NS, Brüggenwirth HT, Modesti M, et al. Dynamic assembly of end-joining complexes requires interaction between Ku70/80 and XRCC4. Proc Natl Acad Sci U S A 2006;103:18597-602. (Pubitemid 44913456)
32. Rao R, Nalluri S, Fiskus W, Savoie A, Buckley KM, Ha K, et al. Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells. Clin Cancer Res 2010;16:4742-54.
33. Fiskus W, Wang Y, Joshi R, Rao R, Yang Y, Chen J, et al. Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells. Clin Cancer Res 2008; 14:6106-15.
34. Geng L, Cuneo KC, Fu A, Tu T, Atadja PW, Hallahan DE. Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma- H2AX foci and confines HDAC4 to the cytoplasm in irradiated nonsmall cell lung cancer. Cancer Res 2006;66:11298-304. (Pubitemid 46009960)
35. Yang Y, Rao R, Shen J, Tang Y, Fiskus W, Nechtman J, et al. Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion. Cancer Res 2008;68:4833-42.
36. Wang B, Matsuoka S, Carpenter PB, Elledge SJ. 53BP1, a mediator of the DNA damage checkpoint. Science 2002;298:1435-8. (Pubitemid 35346146)
37. Modi S, Stopeck AT, Gordon MS, Mendelson D, Solit DB, Bagatell R, et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 2007;25:5410-7. (Pubitemid 350232217)
38. Sessa C, Sharma SK, Britten CD, Vogelzang NJ, Bhalla K, Mita MM,, et al. A phase I dose escalation study of AUY922, a novel HSP90 inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2009;27:15s.
39. Wu X, Shell SM, Liu Y, Zou Y. ATR-dependent checkpoint modulates XPA nuclear import in response to UV irradiation. Oncogene 2007;26:757-64. (Pubitemid 46204254)
40. Tibbetts RS, Cortez D, Brumbaugh KM, Scully R, Livingston D, Elledge SJ, et al. Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress. Genes Dev 2000; 14:2989-3002.
41. Pichierri P, Rosselli F, Franchitto A. Werner's syndrome protein is phosphorylated in an ATR/ATM-dependent manner following replication arrest and DNA damage induced during the S phase of the cell cycle. Oncogene 2003;22:1491-500. (Pubitemid 36390598)
42. Davies SL, North PS, Dart A, Lakin ND, Hickson ID. Phosphorylation of the Bloom's syndrome helicase and its role in recovery from S-phase arrest. Mol Cell Biol 2004;24:1279-91. (Pubitemid 38112189)
43. Andreassen PR, D'Andrea AD, Taniguchi T. ATR couples FANCD2 monoubiquitination to the DNA-damage response. Genes Dev 2004;18:1958-63. (Pubitemid 39071576)
44. Rao R, Fiskus W, Yang Y, Lee P, Joshi R, Fernandez P, et al. HDAC6 inhibition enhances 17-AAG-mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood 2008;112:1886-93.
45. Banerjee S, Kaye SB, Ashworth A. Making the best of PARP inhibitors in ovarian cancer. Nat Rev Clin Oncol 2010;7:508-19.
46. Rowe BP, Glazer PM. Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms. Breast Cancer Res 2010;12:203.